NYSEAMERICAN:MTNB Matinas BioPharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Matinas BioPharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.83 +0.04 (+5.06%) (As of 07/5/2022 12:00 AM ET) Add Compare Share Today's Range$0.79▼$0.8550-Day Range N/A52-Week Range$0.49▼$1.61Volume727,622 shsAverage Volume380,622 shsMarket Capitalization$180.00 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Matinas BioPharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside261.4% Upside$3.00 Price TargetShort InterestHealthy1.19% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.13) to ($0.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.40 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMatinas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Matinas BioPharma has a forecasted upside of 261.4% from its current price of $0.83.Amount of Analyst CoverageMatinas BioPharma has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.19% of the outstanding shares of Matinas BioPharma have been sold short.Short Interest Ratio / Days to CoverMatinas BioPharma has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Matinas BioPharma has recently decreased by 1.53%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMatinas BioPharma does not currently pay a dividend.Dividend GrowthMatinas BioPharma does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MTNB. Previous Next 1.1 News and Social Media Coverage News SentimentMatinas BioPharma has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.Search InterestOnly 4 people have searched for MTNB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Matinas BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Matinas BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Matinas BioPharma is held by insiders.Percentage Held by InstitutionsOnly 12.40% of the stock of Matinas BioPharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Matinas BioPharma are expected to grow in the coming year, from ($0.13) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Matinas BioPharma is -7.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Matinas BioPharma is -7.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMatinas BioPharma has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MTNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address About Matinas BioPharma (NYSEAMERICAN:MTNB) StockMatinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.Read More MTNB Stock News HeadlinesMay 31, 2022 | finance.yahoo.comMatinas BioPharma to Present at the LD Micro Invitational XII ConferenceMay 12, 2022 | seekingalpha.comMatinas BioPharma (MTNB) CEO, Jerome Jabbour on Q1 2022 Results - Earnings Call TranscriptMay 12, 2022 | seekingalpha.comMatinas Biopharma GAAP EPS of -$0.03May 12, 2022 | finance.yahoo.comMatinas BioPharma Reports First Quarter 2022 Financial Results and Operational HighlightsMay 11, 2022 | seekingalpha.comMatinas Biopharma Q1 2022 Earnings PreviewMay 11, 2022 | benzinga.comA Preview Of Matinas BioPharma Hldgs's EarningsMay 5, 2022 | finance.yahoo.comMatinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 12, 2022May 3, 2022 | finance.yahoo.comMatinas BioPharma to Present at the 12th Annual BioNJ BioPartnering ConferenceApril 12, 2022 | msn.comMatinas (MTNB) Up on Deal With BioNTech for mRNA VaccinesApril 11, 2022 | benzinga.comHere's Why Matinas BioPharma Shares Are RisingApril 11, 2022 | finanznachrichten.deBioNTech SE: BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based VaccinesApril 11, 2022 | finance.yahoo.comBioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based VaccinesApril 6, 2022 | finance.yahoo.comMatinas BioPharma to Present at the Needham Virtual Healthcare ConferenceMarch 22, 2022 | finance.yahoo.comMatinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-VestMarch 16, 2022 | finance.yahoo.comMatinas Biopharma Holdings, Inc. (MTNB) Loses 29.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 8, 2022 | benzinga.comMatinas BioPharma: Q4 Earnings InsightsMarch 8, 2022 | seekingalpha.comMatinas Biopharma GAAP EPS of -$0.03 beats by $0.01March 8, 2022 | finance.yahoo.comMatinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational HighlightsMarch 7, 2022 | markets.businessinsider.comHere's what Wall Street expects from Matinas BioPharma's earnings reportMarch 7, 2022 | seekingalpha.comMatinas Biopharma Q4 2021 Earnings PreviewFebruary 28, 2022 | benzinga.comMatinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial and Operational Results on March 8, 2022January 25, 2022 | seekingalpha.comMatinas BioPharma falls 17% amid pipeline, business updates for 2022January 25, 2022 | finance.yahoo.comMatinas BioPharma Provides Business Update and 2022 Strategic OutlookJanuary 20, 2022 | nasdaq.comMatinas Biopharma Holdings, Inc. Common Stock (MTNB)January 18, 2022 | finance.yahoo.comMatinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022See More Headlines Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:MTNB CUSIPN/A CIKN/A Webwww.matinasbiopharma.com Phone(908) 443-1860FaxN/AEmployees31Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/06/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$3.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+261.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,280,000.00 Net MarginsN/A Pretax Margin-69,849.70% Return on Equity-43.92% Return on Assets-38.26% Debt Debt-to-Equity RatioN/A Current Ratio11.97 Quick Ratio11.97 Sales & Book Value Annual Sales$30,000.00 Price / Sales6,000.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book3.46Miscellaneous Outstanding Shares216,870,000Free Float199,299,000Market Cap$180.00 million OptionableNot Optionable Beta1.98 Matinas BioPharma Frequently Asked Questions Should I buy or sell Matinas BioPharma stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Matinas BioPharma stock. View analyst ratings for Matinas BioPharma or view top-rated stocks. What is Matinas BioPharma's stock price forecast for 2022? 2 Wall Street research analysts have issued 1 year price targets for Matinas BioPharma's shares. Their MTNB stock forecasts range from $3.00 to $3.00. On average, they anticipate Matinas BioPharma's share price to reach $3.00 in the next year. This suggests a possible upside of 261.4% from the stock's current price. View analysts' price targets for Matinas BioPharma or view top-rated stocks among Wall Street analysts. How has Matinas BioPharma's stock performed in 2022? Matinas BioPharma's stock was trading at $0.9462 at the start of the year. Since then, MTNB stock has decreased by 12.3% and is now trading at $0.83. View the best growth stocks for 2022 here. When is Matinas BioPharma's next earnings date? Matinas BioPharma is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Matinas BioPharma. How were Matinas BioPharma's earnings last quarter? Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) released its quarterly earnings results on Thursday, May, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). View Matinas BioPharma's earnings history. Who are Matinas BioPharma's key executives? Matinas BioPharma's management team includes the following people: Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 48, Pay $795k)Dr. Theresa Matkovits Ph.D., Chief Devel. Officer (Age 55, Pay $525.52k)Dr. James J. Ferguson FACC, M.D., Chief Medical Officer (Age 67, Pay $586.3k)Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 52)Dr. Hui Liu M.B.A., Ph.D., Chief Technology Officer (Age 54)Dr. Raphael J. Mannino Ph.D., Chief Scientific Officer (Age 75)Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply ChainMr. Thomas J. Hoover M.B.A., Chief Bus. Officer (Age 52) Who are some of Matinas BioPharma's key competitors? Some companies that are related to Matinas BioPharma include Keros Therapeutics (KROS), Y-mAbs Therapeutics (YMAB), CTI BioPharma (CTIC), TG Therapeutics (TGTX), POINT Biopharma Global (PNT), Evolus (EOLS), Nuvalent (NUVL), Northwest Biotherapeutics (NWBO), Organogenesis (ORGO), Gossamer Bio (GOSS), Ventyx Biosciences (VTYX), Mirum Pharmaceuticals (MIRM), Vanda Pharmaceuticals (VNDA), Geron (GERN) and DICE Therapeutics (DICE). View all of MTNB's competitors. What other stocks do shareholders of Matinas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), OrganiGram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS). What is Matinas BioPharma's stock symbol? Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB." How do I buy shares of Matinas BioPharma? Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Matinas BioPharma's stock price today? One share of MTNB stock can currently be purchased for approximately $0.83. How much money does Matinas BioPharma make? Matinas BioPharma (NYSEAMERICAN:MTNB) has a market capitalization of $180.00 million and generates $30,000.00 in revenue each year. The company earns $-23,280,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. How many employees does Matinas BioPharma have? Matinas BioPharma employs 31 workers across the globe. How can I contact Matinas BioPharma? Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The official website for Matinas BioPharma is www.matinasbiopharma.com. The company can be reached via phone at (908) 443-1860 or via email at mtnb@jtcir.com. This page (NYSEAMERICAN:MTNB) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
